Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Galexxy Holdings, Inc. (GXXY)
Newport Beach, CA, US
Galexxy Holdings, Inc. operates as a key supplier within the agricultural sector. The company distinguishes itself by employing unique, proprietary systems and processes that efficiently optimize the use of critical resources – including water, energy, space, capital, and labor – to deliver essential fertilizers and nutrients. Their services are primarily targeted at specialized cultivation industries, with a significant focus on hemp. Its comprehensive product line encompasses a wide array of conventional and organic (non-GMO) fertilizers, vital nutrients, and crop protection solutions, such as pesticides, insecticides, herbicides, and mold treatments. These are distributed via the company's e-commerce platform, retail partners, and wholesale networks. Additionally, Galexxy Holdings offers a patented DRIP irrigation system, suitable for both indoor and outdoor agricultural applications. The company's market reach extends both domestically across the United States and internationally. Founded as AgTech Global International, Inc., the organization rebranded as Galexxy Holdings, Inc. in March 2022. Its corporate headquarters are situated in Newport Beach, California.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -43.48% | -70.45% | -78.33% | +0.00% | -82.67% | -98.63% | -99.76% | -98.70% | -99.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-88.8% Q2'25: -100.0% (vs Q2'24)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-86.4% Q2'25: +100.0% (vs Q2'24)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-2,055.3%
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-2,625.5%
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q2'25: +1.6% (vs Q2'24)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+17.8% Q2'25: +8.5% (vs Q2'24)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.07× Q2'25: -28.33× (vs Q2'24)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| George T. Roth | President & Director | 28.1K | male |
| Michael Biagi | Chief Executive Officer | — | male |
| Rachel Fyffe | Vice President of Communications | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GXXY
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
